Chinese expert consensus on adverse reaction management for dual immunotherapy in hepatocellular carcinoma

Abstract

The Liver Oncology Branch of the China Association for the Promotion of International Exchange in Healthcare, the Immunology Branch of the China Association for the Promotion of International Exchange in Healthcare, the Digestive Tumor Comprehensive Diagnosis and Treatment Branch of the China Association for the Promotion of International Exchange in Healthcare, et al. Chinese expert consensus on adverse reaction management for dual immunotherapy in hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2026, 13(3): 13-28.

References

[1] Zheng RS, Sun KX, Han BF, et al.Cancer incidence and mortality in China, 2024[J]. J Nat Cancer Center, Available online 15 June 2026.
[2] Allemani C, Matsuda T, Di Carlo V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075 .
[3] Jaber F, Cholankeril G, El-Serag HB.Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies[J]. J Can Assoc Gastroenterol, 2024, 7(5): 331-345.
[4] 杨硕,任朦,杨益,等. 489例肝细胞癌患者生存特征及影响因素分析:一项回顾性队列研究[J]. 中西医结合肝病杂志,2025,35(9):1057-1063.
[5] Vitale A, Morales RM, Zanus G, et al.Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study[J]. Lancet Oncol, 2011, 12(7): 654-662.
[6] Feng YQ, Fang LT, Cao GW.Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer[J]. Hepatoma Res, 2025, 11: 5.
[7] Forner A, Reig M, Bruix J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[8] 劳坚强,李文阳,黄朝满,等. 2023—2025年中外肝细胞癌诊疗指南的系统比较与解读及临床实践启示[J]. 中国普通外科杂志,2026,35(1):149-161.
[9] Ren ZG, Xu JM, Bai YX, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[10] Cheng AL, Qin SK, Ikeda M, et al.Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873.
[11] Qin SK, Chan SL, Gu SZ, et al.Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146.
[12] Llovet JM, Kudo M, Merle P, et al.Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(12): 1399-1410.
[13] Zhou J, Bai L, Luo J, et al.Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2025, 26(6): 719-731.
[14] Shi YH, Han GH, Zhou J, et al.Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2025, 10(7): 658-670.
[15] Zhao CH, Zhang YQ, Wang G, et al.Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial[J]. Signal Transduct Target Ther, 2025, 10(1): 249.
[16] Bi XY, Lu YY, Chen B, et al.Chinese expert consensus on the combination of targeted therapy and immunotherapy with locoregional therapy for intermediate/advanced hepatocellular carcinoma[J]. Liver Cancer, 2024, 14(3): 334-350.
[17] Galle PR, Sangro B, Decaens T, et al. Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW[C]. J Clin Oncol, 2026, 44(Suppl 2): LBA479.
[18] Galle PR, Decaens T, Kudo M, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW[J]. J Clin Oncol, 2024, 42(Suppl 17): LBA4008.
[19] Qin S, Bai Y, Han G, et al. Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma: CheckMate 9DW expanded analyses[C]. Lugano: ESMO World Congress on Gastrointestinal Cancers, 2025, Poster #157P.
[20] Esfahani K, Elkrief A, Calabrese C, et al.Moving towards personalized treatments of immune-related adverse events[J]. Nat Rev Clin Oncol, 2020, 17(8): 504-515.
[21] Postow MA, Sidlow R, Hellmann MD.Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168.
[22] Larkin J, Chiarion-Sileni V, Gonzalez R, et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1): 23-34.
[23] Yau T, Kang YK, Kim TY, et al.Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564.
[24] Martins F, Sofiya L, Sykiotis GP, et al.Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance[J]. Nat Rev Clin Oncol, 2019, 16(9): 563-580.
[25] Owen CN, Bai X, Quah T, et al.Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma[J]. Ann Oncol, 2021, 32(7): 917-925.
[26] Durbin SM, Zubiri L, Perlman K, et al.Late-onset immune-related adverse events after immune checkpoint inhibitor therapy[J]. JAMA Netw Open, 2025, 8(3): e252668.
[27] Yau T, Galle PR, Decaens T, et al.Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial[J]. Lancet, 2025, 405(10492): 1851-1864.
[28] Yu Y, Wang S, Su N, et al.Increased circulating Levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer[J]. Front Oncol, 2022, 12: 906824.
[29] Kudo M, Yau T, Decaens T, et al.Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses[J]. J Clin Oncol, 2025, 43(Suppl 4): 520.
[30] Triantafyllou E, Gudd CLC, Possamai LA.Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management[J]. Nat Rev Gastroenterol Hepatol, 2025, 22(2): 112-126.
[31] 华雨薇,赵林.免疫治疗相关肝毒性的诊断与管理[J].协和医学杂志,2021,12(5):798-806.
[32] 雷晓红,唐颖悦,李静,等. 肿瘤免疫检查点抑制剂相关的肝毒性[J]. 中华肝脏病杂志,2020,28(2):175-178.
[33] Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: a review[J]. World J Gastroenterol, 2021, 27(32): 5376-5391.
[34] Kim KW, Ramaiya NH, Krajewski KM, et al.Ipilimumab associated hepatitis: imaging and clinicopathologic findings[J]. Invest New Drugs, 2013, 31(4): 1071-1077.
[35] Alessandrino F, Tirumani SH, Krajewski KM, et al.Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors[J]. Clin Radiol, 2017, 72(7): 521-533.
[36] Lasagna A, Sacchi P.The ABC of immune-mediated hepatitis during immunotherapy in patients with cancer: from pathogenesis to multidisciplinary management[J]. Cancers (Basel), 2024, 16(4): 795.
[37] Thompson JA, Schneider BJ, Brahmer J, et al.NCCN guidelines® insights: management of immunotherapy-related toxicities, version 2.2024[J]. J Natl Compr Canc Netw, 2024, 22(9): 582-592.
[38] Puzanov I, Diab A, Abdallah K, et al.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group[J]. J Immunother Cancer, 2017, 5(1): 95.
[39] Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(Suppl 4): iv119-iv142.
[40] 中国临床肿瘤学会(CSCO). 免疫检查点抑制剂相关不良反应管理指南(2023)[M]. 北京:人民卫生出版社,2023.
[41] Brahmer JR, Lacchetti C, Schneider BJ, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768.
[42] 中华医学会肝病学分会. 肝细胞癌靶向药物及免疫检查点抑制剂相关肝损伤管理共识(2024年版)[J]. 中华肝脏病杂志,2024,32(12): 1086-1097.
[43] 施国,黄晓勇,任正刚,等.肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志,2021,20(12):1241-1258.
[44] 国际肝胆胰协会中国分会,中华医学会外科学分会肝脏外科学组,中国临床肿瘤学会(CSCO)肝癌专家委员会.肝细胞癌免疫联合治疗多学科中国专家共识(2023版)[J].中华消化外科杂志,2023,22(3):293-315.
[45] Zhang N, Li Z, Liu Y, et al.Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics[J]. Hepatol Int, 2024, 18(6): 1770-1780.
[46] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immune checkpoint inhibitor-related toxicities (version 1.2026) [R/OL].(2023-12-07)[2026-08-20]. https://www.pfizermedicalinformation.cn/clinical-guidelines/2497.
[47] Lo BC, Kryczek I, Yu J, et al.Microbiota-dependent activation of CD4+ T cells induce CTLA-4 blockade-associated colitis via Fcγ receptors[J]. Science, 2024, 383(6678): 62-70.
[48] 秦叔逵,白玉贤,韩国宏,等.纳武利尤单抗联合伊匹木单抗对比仑伐替尼或索拉非尼用于不可切除/晚期肝细胞癌患者一线治疗的效果:CheckMate 9DW 研究中国人群分析[C].厦门:第27届全国临床肿瘤学大会暨2024年中国临床肿瘤学会(CSCO)学术年会,2024,2024中国临床肿瘤学会(CSCO)年会论文集.
[49] Decaens T, Yau T, Kudo M, et al. Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: expanded analyses from CheckMate 9DW[C]. Barcelona: Presented at the2024 European Society for Medical Oncology (ESMO) congress, 2024, Abstract No: 965MO.
[50] Braun LM, Lu Y, Zeiser R.Clinical perspective and treatment of immune-related colitis after cancer immunotherapy[J]. Trends Cancer, 2025, 11(11): 1058-1077.
[51] 谭蓓,王汉萍,李玥,等. 免疫检查点抑制剂相关结肠炎八例临床特征分析[J]. 中华消化杂志,2021,41(5):330-335.
[52] Wang S, Wang H.Treatment of immune checkpoint inhibitor-related colitis: a narrative review[J]. Transl Cancer Res, 2024, 13(12): 7002-7014.
[53] Iwama S, Kobayashi T, Arima H.Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors[J]. Nat Rev Endocrinol, 2025, 21(5): 289-300.
[54] Zhu L, Cheung YM, Chiang C, et al.Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors[J]. J Immunother Cancer, 2025, 13(10): e011865.
[55] Husebye ES, Castinetti F, Criseno S, et al.Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline[J]. Eur J Endocrinol, 2022, 187(6): G1-G21.
[56] Quach HT, Johnson DB, LeBoeuf NR, et al. Cutaneous adverse events caused by immune checkpoint inhibitors[J]. J Am Acad Dermatol, 2021, 85(4): 956-966.
[57] 中华医学会皮肤性病学分会,中国医师协会皮肤科医师分会,中国老年医学学会皮肤医学分会.免疫检查点抑制剂相关皮肤不良反应诊治中国专家共识(2024版)[J].中华医学杂志,2024,104(20):1790-1803.
[58] 王妍,陈慧勇,林瑾仪,等.免疫检查点抑制剂相关心肌炎临床诊疗实施建议[J].中国临床医学,2023,30(2):368-391.
[59] Fang J, Zhong S, Wang T, et al.Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study[J]. Gut, 2026, 75(6): 1201-1210.
[60] Wong JSL, Kwok GGW, Tang V, et al.Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors[J]. J Immunother Cancer, 2021, 9(2): e001945.
[61] Alden SL, Lim M, Kao C, et al.Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma[J]. Cancer Res Commun, 2023, 3(7): 1312-1317.
[62] Roessler D, Öcal O, Philipp AB, et al.Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor based combination therapies: a multicenter retrospective study[J]. J Cancer Res Clin Oncol, 2023, 149(7): 3065-3073.
[63] Kim JS, Kang B, An C, et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: a multicenter retrospective study[J]. Ann Oncol, 2024, 35(Suppl 11): S1152-S1153 (Abstract 946P).
[64] Zheng SS, Wu JF, Zhang ZZ, et al.Efficacy and safety of ipilimumab plus anti-PD-1/PD-L1 antibodies combination therapy in advanced hepatocellular carcinoma patients progressing after multiple lines of treatment: a retrospective multicenter study[J]. J Hepatocell Carcinoma, 2025, 12: 527-537.
[65] 中国老年学及老年医学学会转化医学分会,北京医学会肝病学分会,中国临床肿瘤学会肝癌专家委员会.原发性肝细胞癌后线规范化用药专家共识[J].中华肝脏病杂志,2026,34(1):32-48.
[66] Kim JS, Chen SC, Wong JSL, et al.Efficacy of nivolumab plus ipilimumab in advanced hepatocellular carcinoma with and without high-risk features: an international multicenter study[J]. Liver Cancer, 2026.
[67] Kim Y, Kang B, An C, et al.Nivolumab plus ipilimumab in advanced hepatocellular carcinoma with Child-Pugh B: a multicenter retrospective study[J]. J Clin Oncol, 2025, 43(Suppl4): 551.
[68] Kaseb AO, Hasanov E, Cao HST, et al.Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218.
[69] D'Alessio A, Pai M, Spalding D, et al. Neoadjuvant immunotherapy with ipilimumab plus nivolumab leads to radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma[J]. J Clin Oncol, 2023, 41(Suppl 16): 4129.
[70] Lin YJ, Ou DL, Su YY, et al.Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration[J]. J Hepatol, 2026, 84(2): 316-328.
[71] Dayyani F, et al. Cabozantinib in combination with nivolumab/ipilimumab followed by transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC) confined to the liver: a phase Ⅱ study[J]. J Clin Oncol, 2026, 44(Suppl 3): abstr 543P.
[72] Yau T, Zagonel V, Santoro A, et al.Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial[J]. J Clin Oncol, 2023, 41(9): 1747-1757.
[73] Juloori A, Katipally RR, Lemons JM, et al.Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2023, 115(1): 202-213.